Annuncio • Jun 30
BGI Genomics Co., Ltd. to Report First Half, 2026 Results on Aug 22, 2026 BGI Genomics Co., Ltd. announced that they will report first half, 2026 results on Aug 22, 2026 Annuncio • Jun 17
BGI Genomics Co., Ltd. (SZSE:300676) announces an Equity Buyback for CNY 500 million worth of its shares. BGI Genomics Co., Ltd. (SZSE:300676) announces a share repurchase program. Under the program, the company will repurchase up to CNY 500 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 50 per share. The shares purchased will be used for the company's equity incentive plan or employee stock ownership plans. The program will be funded out of the own funds and self-raised funds (including special loans for stock repurchase from financial institutions. The program will be valid till 12 months from board approval date. Board Change • May 20
High number of new directors There are 6 new directors who have joined the board in the last 3 years. CFO, Deputy GM & Non Independent Director Yujue Wang was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annuncio • Apr 25
BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2026 BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2026, at 14:30 China Standard Time. Location: Zone C, No. 9, Yunhua Road, Meisha Subdistrict, Yantian District, Shenzhen, Guangdong China Annuncio • Mar 31
BGI Genomics Co., Ltd. to Report Q1, 2026 Results on Apr 25, 2026 BGI Genomics Co., Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 Annuncio • Dec 31
BGI Genomics Co., Ltd. to Report Fiscal Year 2025 Results on Apr 25, 2026 BGI Genomics Co., Ltd. announced that they will report fiscal year 2025 results on Apr 25, 2026 Annuncio • Sep 30
BGI Genomics Co., Ltd. to Report Q3, 2025 Results on Oct 24, 2025 BGI Genomics Co., Ltd. announced that they will report Q3, 2025 results on Oct 24, 2025 Annuncio • Sep 23
An undisclosed buyer acquired 4% stake in BGI Genomics Co., Ltd. (SZSE:300676) from Shenzhen Huada Gene Technology Co., Ltd. for Approximately CNY 740 million. An undisclosed buyer acquired 4% stake in BGI Genomics Co., Ltd. (SZSE:300676) from Shenzhen Huada Gene Technology Co., Ltd. for Approximately CNY 740 million on September 22, 2025.
An undisclosed buyer completed the acquisition of 4% stake in BGI Genomics Co., Ltd. (SZSE:300676) from Shenzhen Huada Gene Technology Co., Ltd. on September 22, 2025. Annuncio • Jul 02
BGI Genomics Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025 BGI Genomics Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 Annuncio • Apr 26
BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2025 BGI Genomics Co., Ltd., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: Area C, No. 9, Yunhua Road, Meisha Subdistrict, Yantian District, Shenzhen, Guangdong China Annuncio • Mar 31
BGI Genomics Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025 BGI Genomics Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025 Annuncio • Dec 31
BGI Genomics Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025 BGI Genomics Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025 Reported Earnings • Oct 26
Third quarter 2024 earnings released: CN¥0.36 loss per share (vs CN¥0.045 profit in 3Q 2023) Third quarter 2024 results: CN¥0.36 loss per share (down from CN¥0.045 profit in 3Q 2023). Revenue: CN¥954.5m (down 11% from 3Q 2023). Net loss: CN¥142.4m (down CN¥161.0m from profit in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance. Annuncio • Sep 30
BGI Genomics Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024 BGI Genomics Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024 Reported Earnings • Aug 24
Second quarter 2024 earnings released: EPS: CN¥0.013 (vs CN¥0.027 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.013 (down from CN¥0.027 in 2Q 2023). Revenue: CN¥1.05b (down 6.0% from 2Q 2023). Net income: CN¥5.80m (down 44% from 2Q 2023). Profit margin: 0.6% (down from 0.9% in 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 47 percentage points per year, which is a significant difference in performance. Board Change • Jul 18
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CFO, Deputy GM & Non Independent Director Yujue Wang was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jun 29
BGI Genomics Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024 BGI Genomics Co., Ltd. announced that they will report first half, 2024 results on Aug 24, 2024 Annuncio • Jun 28
BGI Genomics Co., Ltd. Announces Final Cash Dividend Plan on A Shares for the Year 2023, Payable on 4 July 2024 BGI Genomics Co., Ltd. announced 2023 final profit distribution plan to be implemented (A shares): cash dividend of CNY 1.0000000 per ten shares (tax included) for the year 2023. Record date is 3 July 2024. Ex-date is 4 July 2024. Payment date is 4 July 2024. Annuncio • Jun 20
BGI Genomics Co., Ltd. Announces Board Appointments BGI Genomics Co., Ltd. announced at the EGM held on June 18, 2024, approved election of Zhu Shida, Zhang Guocheng and Wang Yujue as non-independent director and Hou Zhibo, independent director. Annuncio • May 11
Bgi Genomics Co., Ltd. Approves Cash Dividend for 2023 BGI Genomics Co., Ltd. announced at the AGM held on May 9, 2024, approved Cash dividend/10 shares (tax included): CNY 1.00000000 for 2023. Reported Earnings • Apr 14
Full year 2023 earnings released: EPS: CN¥0.23 (vs CN¥1.96 in FY 2022) Full year 2023 results: EPS: CN¥0.23 (down from CN¥1.96 in FY 2022). Revenue: CN¥4.35b (down 38% from FY 2022). Net income: CN¥92.9m (down 88% from FY 2022). Profit margin: 2.1% (down from 11% in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance. Annuncio • Apr 13
BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024 BGI Genomics Co., Ltd., Annual General Meeting, May 09, 2024, at 14:00 China Standard Time. Annuncio • Mar 30
BGI Genomics Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 BGI Genomics Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 New Risk • Mar 01
New major risk - Revenue and earnings growth Earnings have declined by 5.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 331% Paying a dividend despite having no free cash flows. Earnings have declined by 5.4% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (2.1% net profit margin). Reported Earnings • Mar 01
Full year 2023 earnings released: EPS: CN¥0.22 (vs CN¥1.96 in FY 2022) Full year 2023 results: EPS: CN¥0.22 (down from CN¥1.96 in FY 2022). Revenue: CN¥4.35b (down 38% from FY 2022). Net income: CN¥91.2m (down 89% from FY 2022). Profit margin: 2.1% (down from 11% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 40 percentage points per year, which is a significant difference in performance. Annuncio • Dec 29
BGI Genomics Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2024 BGI Genomics Co., Ltd. announced that they will report fiscal year 2023 results on Apr 13, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.35 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.045 (down from CN¥0.35 in 3Q 2022). Revenue: CN¥1.07b (down 21% from 3Q 2022). Net income: CN¥18.6m (down 87% from 3Q 2022). Profit margin: 1.7% (down from 11% in 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance. New Risk • Aug 13
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 167% The company is paying a dividend despite having no free cash flows. Dividend yield: 1.7% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Payout ratio: 167% Paying a dividend despite having no free cash flows. High level of non-cash earnings (36% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (4.2% net profit margin). Reported Earnings • Aug 12
Second quarter 2023 earnings released: EPS: CN¥0.027 (vs CN¥0.68 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.027 (down from CN¥0.68 in 2Q 2022). Revenue: CN¥1.12b (down 36% from 2Q 2022). Net income: CN¥10.4m (down 96% from 2Q 2022). Profit margin: 0.9% (down from 16% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings. Annuncio • Jul 01
BGI Genomics Co., Ltd. to Report First Half, 2023 Results on Aug 12, 2023 BGI Genomics Co., Ltd. announced that they will report first half, 2023 results on Aug 12, 2023 Annuncio • Jun 01
Bgi Genomics Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on 7 June 2023 BGI Genomics Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares): cash dividend of CNY 10.0000000 per ten shares (tax included) for the year 2022. Record date is 06 June 2023. Ex-date is 07 June 2023. Payment date is 07 June 2023. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.091 (vs CN¥0.81 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.091 (down from CN¥0.81 in 1Q 2022). Revenue: CN¥953.8m (down 33% from 1Q 2022). Net income: CN¥41.3m (down 88% from 1Q 2022). Profit margin: 4.3% (down from 23% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to CN¥75.83, the stock trades at a trailing P/E ratio of 39.2x. Average trailing P/E is 41x in the Biotechs industry in China. Total loss to shareholders of 6.9% over the past three years. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Ya Cao was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.80 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.35 (down from CN¥0.80 in 3Q 2021). Revenue: CN¥1.35b (down 10% from 3Q 2021). Net income: CN¥141.4m (down 57% from 3Q 2021). Profit margin: 11% (down from 22% in 3Q 2021). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥20.98 (vs CN¥1.37 in 2Q 2021) Second quarter 2022 results: EPS: CN¥20.98 (up from CN¥1.37 in 2Q 2021). Revenue: CN¥25.7b (up CN¥23.6b from 2Q 2021). Net income: CN¥1.47b (up 162% from 2Q 2021). Profit margin: 5.7% (down from 27% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 63% compared to a 33% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 27
First quarter 2022 earnings released: EPS: CN¥0.81 (vs CN¥1.29 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.81 (down from CN¥1.29 in 1Q 2021). Revenue: CN¥1.43b (down 8.5% from 1Q 2021). Net income: CN¥330.4m (down 37% from 1Q 2021). Profit margin: 23% (down from 34% in 1Q 2021). The decrease in margin was primarily driven by lower revenue. Over the next year, revenue is expected to shrink by 18% compared to a 44% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Ya Cao was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Valuation Update With 7 Day Price Move • Mar 15
Investor sentiment improved over the past week After last week's 28% share price gain to CN¥98.32, the stock trades at a forward P/E ratio of 39x. Average forward P/E is 34x in the Biotechs industry in China. Total returns to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥62.75 per share. Reported Earnings • Feb 28
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: CN¥3.48 (down from CN¥5.25 in FY 2020). Revenue: CN¥6.70b (down 20% from FY 2020). Net income: CN¥1.43b (down 32% from FY 2020). Profit margin: 21% (down from 25% in FY 2020). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 20%. Over the next year, revenue is forecast to grow 17%, compared to a 37% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 28
Second quarter 2021 earnings released: EPS CN¥1.37 (vs CN¥3.79 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥2.08b (down 37% from 2Q 2020). Net income: CN¥561.0m (down 63% from 2Q 2020). Profit margin: 27% (down from 46% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Executive Departure • Aug 11
Chairman of Scientific Advisory Board Tadataka Yamada has left the company On the 4th of August, Tadataka Yamada's tenure as Chairman of Scientific Advisory Board ended after 5.3 years in the role. We don't have any record of a personal shareholding under Tadataka's name. Tadataka is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 6.17 years. Executive Departure • Aug 05
Chairman of Scientific Advisory Board Tadataka Yamada has left the company On the 3rd of August, Tadataka Yamada's tenure as Chairman of Scientific Advisory Board ended after 5.3 years in the role. We don't have any record of a personal shareholding under Tadataka's name. Tadataka is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 6.17 years. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥114, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 45x in the Biotechs industry in China. Total returns to shareholders of 52% over the past three years. Reported Earnings • Apr 26
First quarter 2021 earnings released: EPS CN¥1.29 (vs CN¥0.35 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥1.56b (up 98% from 1Q 2020). Net income: CN¥525.0m (up 275% from 1Q 2020). Profit margin: 34% (up from 18% in 1Q 2020). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Mar 09
New 90-day low: CN¥125 The company is down 3.0% from its price of CN¥129 on 09 December 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.01 per share. Reported Earnings • Mar 04
Full year 2020 earnings released: EPS CN¥5.23 (vs CN¥0.69 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥8.43b (up 201% from FY 2019). Net income: CN¥2.08b (up CN¥1.80b from FY 2019). Profit margin: 25% (up from 9.9% in FY 2019). The increase in margin was driven by higher revenue. Analyst Estimate Surprise Post Earnings • Mar 04
Revenue misses expectations Revenue missed analyst estimates by 6.2%. Over the next year, revenue is expected to shrink by 36% compared to a 57% growth forecast for the Biotechs industry in China. Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥147, the stock is trading at a trailing P/E ratio of 21.6x, down from the previous P/E ratio of 26.2x. This compares to an average P/E of 64x in the Biotechs industry in China. Total returns to shareholders over the past year are 85%. Is New 90 Day High Low • Jan 21
New 90-day high: CN¥166 The company is up 25% from its price of CN¥133 on 23 October 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥0.93 per share. Valuation Update With 7 Day Price Move • Jan 11
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥148, the stock is trading at a trailing P/E ratio of 21.7x, up from the previous P/E ratio of 18.8x. This compares to an average P/E of 66x in the Biotechs industry in China. Total returns to shareholders over the past year are 117%. Is New 90 Day High Low • Dec 18
New 90-day low: CN¥127 The company is down 10.0% from its price of CN¥142 on 18 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.51 per share. Is New 90 Day High Low • Nov 17
New 90-day low: CN¥132 The company is down 7.0% from its price of CN¥141 on 19 August 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.33 per share. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥2.71b, with earnings increasing by CN¥2.38b from the prior year. Total revenue was CN¥7.48b over the last 12 months, up 168% from the prior year. Is New 90 Day High Low • Oct 23
New 90-day low: CN¥133 The company is down 12% from its price of CN¥151 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥1.22 per share.